Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder.
Humans
Opioid-Related Disorders
/ drug therapy
Buprenorphine
/ administration & dosage
Delayed-Action Preparations
Administration, Cutaneous
Male
Adult
Substance Withdrawal Syndrome
/ drug therapy
Narcotic Antagonists
/ administration & dosage
Female
Opiate Substitution Treatment
/ methods
Injections, Subcutaneous
Middle Aged
Analgesics, Opioid
/ administration & dosage
Buprenorphine, Naloxone Drug Combination
/ administration & dosage
Butrans
Low-dose induction
Micro-dosing buprenorphine
Micro-induction
Subcutaneous
Sublocade
Transdermal
Journal
Addiction science & clinical practice
ISSN: 1940-0640
Titre abrégé: Addict Sci Clin Pract
Pays: England
ID NLM: 101316917
Informations de publication
Date de publication:
18 Jun 2024
18 Jun 2024
Historique:
received:
15
01
2024
accepted:
28
05
2024
medline:
18
6
2024
pubmed:
18
6
2024
entrez:
17
6
2024
Statut:
epublish
Résumé
Buprenorphine is an effective and safe treatment for opioid use disorder, but the requirement for moderate opioid withdrawal symptoms to emerge prior to initiation is a significant treatment barrier. We report on two cases of hospitalized patients with severe, active opioid use disorder, in which we initiated treatment with transdermal buprenorphine over 48 h, followed by the administration of a single dose of sublingual buprenorphine/naloxone and then extended-release subcutaneous buprenorphine. The patients did not experience precipitated withdrawal and only had mild withdrawal symptoms. This provides preliminary evidence for a rapid induction strategy that may improve tolerability, caregiver burden, and treatment retention as compared to previous induction strategies.
Sections du résumé
BACKGROUND
BACKGROUND
Buprenorphine is an effective and safe treatment for opioid use disorder, but the requirement for moderate opioid withdrawal symptoms to emerge prior to initiation is a significant treatment barrier.
CASE PRESENTATION
METHODS
We report on two cases of hospitalized patients with severe, active opioid use disorder, in which we initiated treatment with transdermal buprenorphine over 48 h, followed by the administration of a single dose of sublingual buprenorphine/naloxone and then extended-release subcutaneous buprenorphine. The patients did not experience precipitated withdrawal and only had mild withdrawal symptoms.
CONCLUSIONS
CONCLUSIONS
This provides preliminary evidence for a rapid induction strategy that may improve tolerability, caregiver burden, and treatment retention as compared to previous induction strategies.
Identifiants
pubmed: 38886826
doi: 10.1186/s13722-024-00479-1
pii: 10.1186/s13722-024-00479-1
doi:
Substances chimiques
Buprenorphine
40D3SCR4GZ
Delayed-Action Preparations
0
Narcotic Antagonists
0
Analgesics, Opioid
0
Buprenorphine, Naloxone Drug Combination
0
Types de publication
Journal Article
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
50Informations de copyright
© 2024. The Author(s).
Références
Clin Toxicol (Phila). 2022 Jun;60(6):688-693
pubmed: 35048759
Drugs. 2009;69(5):577-607
pubmed: 19368419
Am J Addict. 2020 Nov;29(6):531-535
pubmed: 32346944
EClinicalMedicine. 2023 Nov 17;66:102311
pubmed: 38045803
Addict Sci Clin Pract. 2021 Feb 12;16(1):11
pubmed: 33579359
Am J Addict. 2019 Jul;28(4):262-265
pubmed: 30901127
Clin Drug Investig. 2021 May;41(5):425-436
pubmed: 33818748
Clin Pharmacokinet. 2021 Apr;60(4):527-540
pubmed: 33135125
J Addict Med. 2023 Mar-Apr 01;17(2):233-236
pubmed: 36149002
J Psychoactive Drugs. 2003 Apr-Jun;35(2):253-9
pubmed: 12924748
JAMA. 2016 Jul 19;316(3):282-90
pubmed: 27434441
Pain Med. 2018 Oct 1;19(10):1988-1996
pubmed: 29036723
JAMA Netw Open. 2021 May 3;4(5):e219041
pubmed: 33970256
Subst Abuse Rehabil. 2016 Jul 20;7:99-105
pubmed: 27499655
Am J Addict. 2011 Sep-Oct;20(5):480-1
pubmed: 21838850
J Neurosci Rural Pract. 2012 Jan;3(1):45-50
pubmed: 22346191
J Psychoactive Drugs. 2014 Nov-Dec;46(5):412-26
pubmed: 25364994